Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSGlobeNewsWire · Oct 19, 2026
Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN)Defense World · Oct 19, 2026
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 DecisionMarketBeat · Oct 2, 2026
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of “Moderate Buy” from BrokeragesDefense World · Sep 30, 2026
Clene to Present at Upcoming Investor ConferencesGlobeNewsWire · Sep 22, 2026
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDAGlobeNewsWire · Sep 21, 2026Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.37 | -$1.08 | Miss |
| May 14, 2026 | -$0.50 | -$0.69 | Miss |
| Mar 12, 2026 | -$0.74 | -$0.93 | Miss |
| Nov 13, 2025 | -$0.60 | -$0.85 | Miss |
| Aug 14, 2025 | -$0.49 | -$0.78 | Miss |
| May 7, 2025 | -$0.95 | -$0.09 | Beat |